<DOC>
	<DOCNO>NCT00477711</DOCNO>
	<brief_summary>The purpose study investigate whether cetuximab ( Erbitux® ) cisplatin capecitabine ( Xeloda ) 1st line treatment advance gastric cancer effective .</brief_summary>
	<brief_title>A Study Cetuximab ( Erbitux ) With Cisplatin Capecitabine ( Xeloda ) 1st Line Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>Gastric cancer remain one major cause cancer death around world , especially Asia . Previous study ML17032 prove XP ( capecitabine plus cisplatin ) effective advanced gastric cancer , overall response rate 41 % , median PFS 5.6 month . Recently , EGFR monoclonal antibody cetuximab show successful treating advance colorectal cancer without chemotherapy . Since EGFR also express gastric cancer , A single arm , open , multicenter phase II study cetuximab combination cisplatin capecitabine first line treatment patient advance gastric cancer.If applicable , value mutation k-ras , b-raf , P53 , EGFR copy number predict clinical response cetuximab advance gastric cancer patient also accessed.Tumor tissue study patient check k-ras , b-raf , P53 mutation sequence EGFR copy number chromogenic situ hybridization . DNA extract paraffin-embedded sample .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Having sign informed consent Age 18 75 year old Histologically confirm gastric adenocarcinoma Unresectable recurrent metastatic disease Previous neoadjuvant adjuvant treatment gastric cancer , applicable , 12 month Measurable disease accord RECIST criterion Karnofsky performance status ≥60 Life expectancy ≥2 month No prior radiotherapy except radiotherapy nontarget lesion study 4 week ALT AST &lt; 2.5 time ULN ( ≤5 time ULN patient liver metastasis ) Serum albumin level ≥3.0g/dL Serum AKP &lt; 2.5 time ULN Serum creatinine &lt; 1.5mg/dL Bilirubin level &lt; 1.5mg/dL Serum creatinine &lt; 1.5 time ULN WBC &gt; 3,000/mm3 , absolute neutrophil count ≥2000/mm3 , platelet &gt; 100,000/mm3 , Hb &gt; 9g/dl Brain metastasis ( know suspect ) Previous systemic therapy metastatic gastric cancer Inability take oral medication Previous EGFR pathwaytargeting therapy Surgery ( exclude diagnostic biopsy ) within 4 week prior study entry Heart failure , coronary artery disease , myocardial infarction within last 6 month Known allergy study treatment Pregnancy lactation period Any investigational agent within past 28 day Other previous malignancy within 5 year , except nonmelanoma skin cancer Previous adjuvant therapy capecitabine+platinum Preexisting neuropathy &gt; grade 1 Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>cisplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>first line treatment</keyword>
</DOC>